IAS Conference

Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.

A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.

The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.

Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

Impaired resilience was found to be associated with loneliness.

Virtual support services were crucial for providing continued care and education.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.

Many respondents reported having a lack of information about the use of PrEP.

PLWH should strictly maintain ART therapy and COVID-19 mitigation efforts.

Crowdsourcing and other approaches may develop more effective interventions to promote PS.

More tailored strategies could improve PrEP provision in family planning clinics.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.

Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.

No significant difference was observed across the 3 study groups.

A positive relationship may exist between infection severity and adaptive immunity.

In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.

Rates of testing for HIV, as well as PrEP uptake, remain suboptimal in MSM of color.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.

New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.

Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.

A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.

Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.

The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.

At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.

GEMINI 1 & 2 are phase 3, randomized, double-blind, multicenter studies evaluating the 2-drug regimen of DTG/3TC in comparison with the 3-drug regimen of DTG + TDF/FTC.